Imfinzi Approved to Reduce Risk of NSCLC Progression – Regulatory Focus
Regulatory Focus |
Imfinzi Approved to Reduce Risk of NSCLC Progression
Regulatory Focus AstraZeneca's immunotherapy Imfinzi (durvalumab) is now approved to reduce the risk of non-small-cell lung cancer (NSCLC) progression in patients with stage III disease whose tumors cannot be surgically removed after treatment with chemotherapy and … US FDA APPROVES IMFINZI® (DURVALUMAB) FOR UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER |
